Table 1.
The Clinical Timeline of Case 1 and 2
| Date | Patient 1 | Patient 2 | ||||||
|---|---|---|---|---|---|---|---|---|
| Events | Antigens | Xp/CT | Treatments | Events | Antigens | Xp/CT | Treatments | |
| 1 year ago | CHOP+ obinutuzumab | LD | ||||||
| 7 months ago | 1st vaccine | |||||||
| 6 months ago | 2nd vaccine | 1st Vaccine | ||||||
| 5 months ago | 2nd Vaccine | |||||||
| Day 0 | PCR (+) | PCR (+) | ||||||
| Day 2 | 1st admission | >5000 | None | Sotrovimab | Home | |||
| Day 9 | Discharge | |||||||
| Day 10 | University Hospital | 217 | GGOs | RDV, DEX start | ||||
| Day 11 | HFNC | DEX off | ||||||
| Day 12 | Bell’s palsy | PSL 50 mg start | 2.18 | Sotorovimab, g-glb | ||||
| Day 15 | None | DEX restart | ||||||
| Day 20 | mPSL 50 mg start | |||||||
| Day 23 | 482 | MPV start | ||||||
| Day 28 | 2nd admission | 3024 | IP shadows | RDV start | ||||
| Day 30 | 1.36 | Improved | ||||||
| Day 32 | Fever up | DEX start | O2 off | |||||
| Day 34 | 126 | |||||||
| Day 40 | University hospital | 2237 | GGOs | Survived, discharge | ||||
| Day 41 | >5000 | G-CSF, MPV start | ||||||
| Day 45 | 2454 | IP shadows | mPSL 500 mg start | |||||
| Day 48 | mPSL 50 mg start | |||||||
| Day 52 | HFNC | >5000 | GGOs | |||||
| Day 60 | Dead | |||||||
Abbreviations: GGOs, ground glass opacities; CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone; DEX, dexamethasone; G-CSF, granulocyte-colony stimulating factor; HFNC, high flow nasal cannula; IP, interstitial pneumonitis; LD, lenalidomide and dexamethasone; mPSL, methylprednisolone; MPV, molnupiravir; PCR, polymerase chain reaction; RDV, remdesivir, respectively.